BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma


Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

Related Videos
C. Ola Landgren, MD, PhD
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Muhamed Baljevic, MD, FACP
Muhamed Baljevic, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Sundar Jagannath, MBBS
S. Vincent Rajkumar, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"